It inhibited the proliferation of bladder cancer cells overexpressing wild-type FGFR3 and demonstrated significant anticancer activity in RT112 bladder cancer xenografts (Guagnano et al., 2011). This evidence concerns the gene FGFR3 and urinary bladder cancer.